Evidence that endogenous heparin activity deficiency may be an important factor in atherogenesis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 2, 1997, Pages 159-166

  Engelberg, Hyman ^a  

^a California Arteriosclerosis Res F   (United States)

Author keywords

Atherosclerosis; Cytokines; Endogenous heparin; Heparin like substances; Inflammation

Indexed keywords

CYTOKINE; HEPARIN; HEPARINOID;

ATHEROSCLEROSIS; FEMALE; HUMAN; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030921390     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996085     Document Type: Review

References (86)

1. Graham DW, TP Lyon, JW Gofman, et al: Blood lipids and atherosclerosis. II. The influence of heparin upon lipoprotein metabolism. Circulation 4:666-676, 1951.
2. Engelberg H, A Dudley, L Freeman: An improved method for the determination of plasma heparin. J Lab Clin Med 46:653-659, 1955.
3. Engelberg H: Plasma heparin levels in normal man. Circulation 23:578-581, 1961.
4. Engelberg H: Plasma heparin levels in normal man: Correlation with serum cholesterol and very low density lipoproteins. Circulation 23:573-577, 1961.
5. Jacobsson KG, U Lindahl: Attempted determination of endogenous heparin in blood. Thromb Haemostas 42:84 (Abstr), 1979.
6. Cavari S, L Stramaccia, S Vanucchi: Endogenous heparinase-sensitive anticoagulant activity in human plasma. Thromb Res 67: 157-165, 1992.
7. Snow AD, R Kisilevsky, C Stephens, T Anastassiades: Electrophoresis of glycosaminoglycans isolated from normal human plasma. Direct evidence for the presence of a heparin-like molecule. Biomed Biochim Acta 7:537-546, 1987.
8. Volpi N, M Cusmano, T Venturalli: Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1243:49-58, 1995.
9. Engelberg H: Human endogenous lipemia clearing factor. Am J Physiol 181:2-5, 1955.
10. Engelberg H: Human endogenous lipemia clearing activity; studies of lipolysis and effects of inhibitors. J Biol Chem 222:601-606, 1956.
11. Engelberg H: In vitro studies of human plasma lipolytic activity before and after oral fat intake. J Appl Physiol 11:2-6, 1957.
12. Engelberg H: Human endogenous plasma lipemia clearing activity: Observations in 482 individuals. J Appl Physiol 13:375-382, 1958.
13. Karpe F, T Olivecrona, G Waldius, et al: Lipoprotein lipase in plasma after an oral fat load: Relation to free fatty acids. J Lipid Res 33:975-984, 1992.
14. Durrington PN: How HDL protects against atheroma. Lancet 342:1315-1316, 1993.
15. Engelberg H: Heparin and the Prevention of Atherosclerosis: Basic Research and Clinical Application. Wiley-Liss, New York, 1990.
16. Auverx JH, SP Babirak, WY Fujimoto, et al: Defective enzyme protein in lipoprotein lipase deficiency. Eur J Clin Invest 19: 433-437, 1989.
17. Beg O, MS Meng, SL Skarlatos, et al: Lipoprotein lipase Bethesda: A single amino acid substitution leads to abnormal binding and to loss of enzyme activity. Proc Natl Acad Sci USA 87:3474-3478, 1990.
18. Cupp M, A Bensadoun, K Melford: Heparin decreases the degradation rate of lipoprotein lipase in adipocytes. J Biol Chem 262: 6343-6348, 1987.
19. Vannier C, G Ailhaud: Biosynthesis of lipoprotein lipase in cultured adipocytes. H. Processing, subunit assembly and intracellular transport. J Biol Chem 264:13206-13216, 1989.
20. Saxena U, MG Klein, IJ Goldberg: Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci USA 88:2254-2258, 1991.
21. Benlian P, JL DeGamma, L Faubert, H Zhang, SE Gagne, M Hayden: Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335:848-854, 1996.
22. Patsch JR, G Miesenbock, T Hopperweiser, et al: Relation of triglyceride metabolism and coronary artery disease: Studies in the postprandial state. Arterioscler Thromb 12:1336-1345, 1992.
23. Uiterwaal CSPM, DE Grobee, JCM Witteman, et al: Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med 121:576-583, 1994.
24. Ryer JE, G Howard, TE Craven, MG Bond, AP Hagaman, JR Crouse III: Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 23:823-828, 1992.
25. Simionescu M, N Simionescu: Functions of the endothelial cell surface. Annu Rev Physiol 48:279-293, 1986.
26. Skutelsky F, D Danon: Redistribution of surface anionic sites on the luminal front of blood vessel endothelium after interaction with polycationic ligand. J Cell Biol 71:232-238, 1976.
27. Gorog P, GVR Born: Increased uptake of circulating low density lipoproteins and fibrinogen by arterial walls after removal of sialic acids from the endothelial surface Br J Exp Pathol 63:447-455, 1982.
28. Thornton SC, SN Mueller, EM Levine: Human endothelial cells: Use of heparin in cloning and long-term serial cultivation. Science 222:623-625, 1983.
29. Engelberg H: Actions of heparin in the atherosclerotic process. Pharmacol Rev 48:327-352, 1996.
30. Stary HC, AB Chandler, S Glagov, et al: A definition of initial fatty streak and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis. American Heart Association. Arterioscler Thromb 14:840-856, 1994.
31. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration. Cell 76:301-314, 1994.
32. Foxall C, SR Watson, D Dobenko, et al: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl-Lewis oligosaccharide. J Cell Biol 117:895-902, 1992.
33. Nelson RM, D Ceccioni, WG Roberts, A Aruffo, RJ Linhardt, MP Bevilacqua: Heparin oligosaccharides bind L- and P-selectins and inhibit acute inflammation. Blood 82:3253-3258, 1993.
34. x and sulfated glycans modulate this binding. Biochem Biophys Res Commun 181:123-130, 1991.
35. Tangelder GJ, K-E Arfors: Inhibition of leukocyte rolling in venules by sulfated polysaccharides. Fed Proc 46:1542 (Abstr), 1987.
36. Lindbom L, X Xie, J Raud, P Hedquist: Chemoattractant-induced firm adhesion of leukocytes to vascular endothelium in vivo is critically dependent on initial leukocyte rolling. Acta Physiol Scand 146:415-421, 1992.
37. Miller MD, MS Krangel: Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17-46, 1992.
38. Valente AH, SR Fowler, EA Sprague, JL Kelley, CA Suenram, CJ Schwartz: Initial characterization of a peripheral blood mononuclear cell chemoattractant derived from cultured arterial smooth muscle cells. Am J Pathol 117:409-413, 1984.
39. Rollins BJ, T Yoshimura, EJ Leonard, JS Pober: Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1. Am J Pathol 136:1229-1233, 1990.
40. Kubes P, M Suzuki, DN Grainger: Platelet activating factor-induced microvascular dysfunction: Role of adherent leukocytes. Am J Physiol 258:G158-163, 1990.
41. Hocking D, TJ Furo, A Johnson: Dextran sulfate and heparan sulfate inhibit platelet activating factor-induced pulmonary edema. J Appl Physiol 72:179-185, 1992.
42. 2 by heparin. Biochim Biophys Acta 1046:242-248, 1990.
43. Dua R, W Cho: Inhibition of human secretory class II PLA. by heparin. Eur J Biochem 221:481-490, 1994.
44. Heller RA, M Kronke: Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 126:5-9, 1994.
45. Silvestro L, C Ruiken, F Sommer, TM Duc, L Biancone, G Montracchio, G Camussi: Platelet activating factor-induced endothelial cell expression of adhesion molecules and modulation of surface glycocalyx. evaluated by electron microscopy chemical analysis. Semin Thromb Hemostas 20:214-222, 1994.
46. Tipping PG, WW Hancock: Production of tumor necrosis factor and interleukin-1 by macrophages from human atherosclerotic plaques. Am J Pathol 142:1721-1728, 1993.
47. Hasuda DJ, J Stricker, PL Simon, PR Young: Processing of precursor interleukin-1B and inflammatory disease. J Biol Chem 265:6318-6322, 1990.
48. Seifert PS, MD Kazatchkine: The complement system in athero-sclerosis. Atherosclerosis 73:91-104, 1988.
49. Weiler JM, RE Edens, RJ Linhardt, DP Kapelanski: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 148:3210-3215, 1992.
50. Platt JL, GM Vercellotti, BL Lindman, et al: Release of heparin sulfate from endothelial cells: Implications for pathogenesis of hyperacute rejection. J Exp Med 171:1383-1388, 1990.
51. Wang Y, Q Hu, JA Madri, SA Rollins, A Chodera A, LA Matis: Amelioration of lupus-like autoimmune disease in mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563-8568, 1996.
52. Steinman L: Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302, 1996.
53. Engelberg H: Serum lipemia: An overlooked cause of tissue hypoxia. Cardiology 70:273-279, 1983.
54. Simonson MB: Endothelins: Multifunctional renal peptides. Physiol Rev 73:375-402, 1993.
55. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064, 1992.
56. Cooke JP, P Tsao: Cellular mechanisms of atherogenesis and the effects of nitric oxide. Curr Opin Cardiol 7:799-804, 1992.
57. Kourembanas S, LP McMillan, GK Leung, DV Fuller: Nitric oxide regulates the expression of vasoconstrictors by vascular endothelial cells under both normoxia and hypoxia. J Clin Invest 92:99-104, 1993.
58. Luscinskas FW, MA Gimbrone Jr: Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 47:413-421, 1996.
59. Nabel EG, AP Selwyn, P Ganz: Large coronary arteries in humans are responsive to changing blood flow: An endothelium dependent mechanism that fails in patients with atherosclerosis, J Am Coll Cardiol 16:349-356, 1990.
60. Celermaier DS, KE Sorenson, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115, 1992.
61. Zieher AM, H Drexler, H Wollschläger, H Just: Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 84:1984-1992, 1991.
62. Yokokowa K, H Takara, M Kohno, et al: Heparin regulates endothelin production through endothelial-derived nitric oxide in human endothelial cells. J Clin Invest 92:2080-2085, 1993.
63. Light JT Jr, JA Bellan, MP Roberts, et al: Heparin treatment enhances the recovery of neoendothelial acetylcholine-induced vascular relaxation after balloon catheter injury in the rabbit aorta. Circulation 88(Suppl 2):413-419, 1993.
64. Schini VS, S Catovsky, W Durante, T Scott-Burden, AI Schafer, PM Vanhoutte: Thrombin inhibits production of nitric oxide synthase in vascular smooth muscle cells. Am J Physiol 264:H611-616, 1993.
65. Edelman ER, LA Pukac, MJ Karnovsky: Protamine and protamine-insulin exacerbate the vascular response to injury. J Clin Invest 91:2308-2313, 1993.
66. Herman IM: Endothelial cell matrices modulate smooth muscle cell growth, contractile phenotype, and sensitivity to heparin. Haemostasis 20(Suppl 1):166-177, 1990.
67. McCaffrey TA, AC Nicholson, PE Szabo, MK Weksler, BB Weksler: Aging and arteriosclerosis: The increased proliferation of smooth muscle cells isolated from old rats is associated with increased PDGF-like activity. J Exp Med 167:163-174, 1988.
68. Campbell JH, GR Campbell: Endothelial cell influences on vascular smooth muscle cell phenotype. Annu Rev Physiol 48:295-306, 1986.
69. Edwards IJ, WD Wagner: Cell surface heparan sulfate proteoglycans and chondroitin sulfate proteoglycans of arterial smooth muscle cells. Am J Pathol 140:193-205, 1992.
70. Aviezar D, A Yayon: Heparin-dependent binding and auto-phosphorylation of epidermal growth factor (EGF) by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA 91:12173-12177, 1994.
71. Schwartz CJ, AJ Valente, JL Kelley, EA Sprague, EH Edwards: Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemostas 14:89-95, 1988.
72. Nachman RL: Thrombosis and atherogenesis: Molecular connections. Blood 79:1897-1906, 1992.
73. Nelson S, W Jeske, D Hoppenstaedt, J Fareed: Tissue factor inhibitor release after the administration of low molecular weight heparin and synthetic sulfated agents. FASEB J 7:Abstr 1211, 1993.
74. Gori AM, M Attanasio, M Francesca, B Giusti, R Abbate, GF Gensini, GG Neri Serneri: Monocyte tissue factor is influenced by heparin. Thromb Haemostas 69:1107 (Abstr), 1993.
75. Görög P, J Piper, CD Ridler, IB Kovacs: Heparin, both unfractionated and low molecular weight, inhibit physiologically relevant platelet reactivity in native blood in vitro. Thromb Haemostas 65:934 (Abstr), 1991.
76. Prisco B, R Paniccia, GF Gensini, M Coppo, A Colella, M Filippini, T Brunelli, R Abbate, GG Neri Serneri: Effect of low dose heparin treatment of fibrinolysis in patients with previous myocardial infarcts. Haemostasis 23:303-313, 1993.
77. Engelberg H: Low-dose intermittent heparin therapy decreases plasma fibrinogen levels. Semin Thromb Hemostas 17:211-215, 1991.
78. Varki A: Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:97-130, 1993.
79. Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis 9:1-20, 1989.
80. Jackson RL, SJ Busch, AD Cardin: Glycosaminoglycans: Molecular properties, protein interactions, and their role in physiological processes. Physiol Rev 71:481-539, 1991.
81. Bernfield M, R Kokenyesi, M Kato, et al: Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8:363-393, 1992.
82. Esko JD: Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3:805-816, 1991.
83. Keller KL, PR Brauer, JM Keller: Isolation of Swiss 3T3 cell variants with altered heparan sulfate. Exp Cell Res 179:137-158, 1988.
84. Engelherg H, R Kuhn, M Steinman: A controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis. Circulation 13:489-498, 1956.
85. Bottiger LE, LA Carlson, L Oro: Long-term heparin treatment in ischemic heart disease: Effects on clinical condition and plasma lipids. Acta Med Scand 182:245-253, 1967.
86. Neri Serneri GG, GF Gensini, M Carnovali, F Rovelli, S Pirelli, A Fortini: Effectiveness of low-dose heparin in prevention of myocardial infarction. Lancet 1:937-942, 1987.